Evidence map›Paper›PMID 27141449›Full record

ReviewTranslational andrology and urology2016

Beyond testosterone cypionate: evidence behind the use of nandrolone in male health and wellness.

Michael M Pan, Jason R Kovac

Open access · hybridAbstract readReview
In one paragraph

Review in Translational andrology and urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Nandrolone Decanoate: Use, Abuse and Side Effects.Medicina (Kaunas, Lithuania) · 2020
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Anabolic Steroids in Fattening Food-Producing Animals-A Review.Animals : an open access journal from MDPI · 2022
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Michael M Pan1 Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA ; 2 Men's Health Center, Urology of Indiana, Indianapolis, Indiana 46260, USA.
Jason R Kovac1 Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA ; 2 Men's Health Center, Urology of Indiana, Indianapolis, Indiana 46260, USA.
Urology of Indiana · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Characterized by low serum testosterone levels and diverse symptoms, male hypogonadism is a common condition. Current medical treatment focuses on testosterone supplementation using multiple modalities such as injections, gels and pellets. Interestingly, while testosterone is considered an anabolic androgenic steroid, it has not been saddled with the social stigma that other, similar medications have. The goal of this review is to highlight an anabolic steroid, 19-nortestosterone (i.e., nandrolone, deca-durabolin) and illustrate prospective therapeutic applications for male health. Containing a chemical structure similar to testosterone, nandrolone has a higher myotrophic: androgenic ratio resulting in improved effects on muscle mass. Animal models have suggested application in the improvement of joint healing following rotator cuff repair. Minimal literature exists regarding the use of nandrolone and, as such, further human studies are required.

Indexed as

alopeciaerectile dysfunction (ED)joint healingmuscle growthNandrolonepharmacologytestosterone supplementation therapy (TST)

Identifiers

PMID27141449
PMCPMC4837307
OpenAlexW2302844697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.